Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-961-1891
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
Employees24
OptionableOptionable
Savara (NASDAQ:SVRA) Frequently Asked Questions
What is Savara's stock symbol?
Savara trades on the NASDAQ under the ticker symbol "SVRA."
How were Savara's earnings last quarter?
Savara Inc (NASDAQ:SVRA) released its earnings results on Thursday, August, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.02. View Savara's Earnings History.
When is Savara's next earnings date?
What price target have analysts set for SVRA?
4 brokerages have issued 12 month price objectives for Savara's stock. Their forecasts range from $12.00 to $40.00. On average, they anticipate Savara's stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 260.8% from the stock's current price. View Analyst Price Targets for Savara.
What is the consensus analysts' recommendation for Savara?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Savara.
What are Wall Street analysts saying about Savara stock?
Here are some recent quotes from research analysts about Savara stock:
- 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (2/12/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $22/share is based on an equally weighted composite of: (a) $22/share, as a 30x multiple of taxed and diluted $5.47 discounted back to FY18 at 25% (in line with the expected PE multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $22/share (discounted cash flow analysis using a 14% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (11/8/2018)
Has Savara been receiving favorable news coverage?
Media stories about SVRA stock have trended positive on Monday, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Savara earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Savara's key competitors?
Some companies that are related to Savara include Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Homology Medicines (FIXX), Advanz Pharma (CXRXF), Retrophin (RTRX), CannTrust (CNTTF), Athenex (ATNX), ImmunoGen (IMGN), Radius Health (RDUS), CytomX Therapeutics (CTMX), G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Arvinas (ARVN) and Intra-Cellular Therapies (ITCI).
Who are Savara's key executives?
Savara's management team includes the folowing people:
- Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
- Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
- David L. Lowrance, Chief Financial Officer (Age 50)
- Nevan C. Elam, Independent Director (Age 49)
- Richard J. Hawkins, Independent Director (Age 68)
- Joseph S. McCracken Ph.D., Independent Director (Age 64)
- Matthew Pauls J.D., Independent Director (Age 46)
- Yuri Pikover, Independent Director (Age 56)
Who are Savara's major shareholders?
Savara's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.26%), Great Point Partners LLC (5.18%), Sectoral Asset Management Inc (2.41%), Geode Capital Management LLC (0.88%), Sphera Funds Management LTD. (0.31%) and Millennium Management LLC (0.27%). Company insiders that own Savara stock include David L Lowrance, Jaakko Taneli Jouhikainen, Joseph S Mccracken, Robert N Neville and Yuri Pikover. View Institutional Ownership Trends for Savara.
Which institutional investors are selling Savara stock?
SVRA stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC and Sphera Funds Management LTD.. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen and Robert N Neville. View Insider Buying and Selling for Savara.
Which institutional investors are buying Savara stock?
SVRA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Virtus ETF Advisers LLC, Sectoral Asset Management Inc, BlackRock Inc., Alps Advisors Inc., Geode Capital Management LLC, D. E. Shaw & Co. Inc. and Rhumbline Advisers. Company insiders that have bought Savara stock in the last two years include David L Lowrance, Jaakko Taneli Jouhikainen, Joseph S Mccracken, Robert N Neville and Yuri Pikover. View Insider Buying and Selling for Savara.
How do I buy shares of Savara?
Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Savara's stock price today?
One share of SVRA stock can currently be purchased for approximately $6.86.
How big of a company is Savara?
Savara has a market capitalization of $240.98 million and generates $130,000.00 in revenue each year. The company earns $-29,790,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Savara employs 24 workers across the globe.
What is Savara's official website?
How can I contact Savara?
Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]
MarketBeat Community Rating for Savara (NASDAQ SVRA)
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
